艾瑞卡联合恩度对晚期NSCLC临床疗效及肿瘤标志物影响  

Clinical efficacy of AiRuiKa combined with Endostar in advanced non-small cell lung cancer and its impact on tumor markers

作　　者：许艳辉 贾同磊 曹新超 贺丽君 马平 XU Yanhui;JIA Tonglei;CAO Xinchao;HE Lijun;MA Ping(Department of Pulmonary Disease,Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine,Cangzhou 061000,China)

机构地区：[1]河北省沧州中西医结合医院肺病科,河北沧州061000 [2]沧州市人民医院胸外科

出　　处：《青岛大学学报(医学版)》2025年第1期104-108,共5页Journal of Qingdao University(Medical Sciences)

基　　金：河北省医学科学研究课题计划项目(20242172)。

摘　　要：目的探讨重组人血管内皮抑制素(恩度)联合卡瑞利珠单抗(艾瑞卡)治疗晚期非小细胞肺癌(NSCLC)的临床效果及其对相关肿瘤标志物的影响。方法2020年6月—2023年5月,河北省沧州中西医结合医院收治接受艾瑞卡治疗的晚期NSCLC病人96例,对其临床资料进行回顾性分析。根据治疗方式分为对照组和联合组,每组48例。对照组给予艾瑞卡+培美曲赛+顺铂等药物治疗,联合组在对照组用药基础上每周期加用恩度治疗。对比分析两组临床疗效、生存质量QLQ-C30评分、肿瘤标志物表达及不良反应发生率等指标。结果治疗6周期后,联合组近期总缓解率和疾病控制率分别为58.3%和85.4%,均显著高于对照组的35.4%和60.4%(χ^(2)=5.061、7.596,P均<0.05)。两组病人生存质量评分均显著升高(t=35.585、35.830,P<0.05),但联合组的生存质量评分升高程度明显优于对照组(t=3.373、11.264,P<0.05)。两组病人癌胚抗原(CEA)和细胞角质蛋白19片段抗原21-1(Cyfra21-1)均显著降低(t=16.691~28.013,P<0.05),但联合组CEA和Cyfra21-1的降低程度均优于对照组(t=2.175~8.658,P均<0.05)。两组病人胃肠道反应、贫血、白细胞计数减少、疲劳和心律失常发生率等比较差异均无统计学意义(P>0.05);对照组皮疹发生率(56.2%)明显高于联合组(29.2%),差异有显著性(χ^(2)=7.195,P<0.05)。结论艾瑞卡联合恩度治疗晚期NSCLC能够提高临床效果和病人的生活质量,降低肿瘤标志物水平和皮疹发生率,安全性较高。Objective\To investigate the clinical efficacy of AiRuiKa combined with Endostar in the treatment of advanced non-small cell lung cancer(NSCLC)and its impact on relevant tumor markers.Methods\A retrospective analysis was performed on the clinical data of 96 patients with advanced NSCLC who received treatment with AiRuiKa at the Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine in Hebei Province from June 2020 to May 2023.According to the treatment method,the patients were divided into control group and combination group,with 48 cases in each group.The control group received medications including AiRuiKa+pemetrexed+cisplatin,while the combination group received Endostar in addition to those for the control group.The clinical efficacy,EORTC QLG Core Questionnaire(EORTC QLQ-C30)score,tumor markers,and incidence of adverse reactions were compared between the two groups.Results\After 6 cycles of treatment,the short-term overall response rate and disease control rate in the combination group were 58.3%and 85.4%,respectively,which were significantly higher than those in the control group(35.4%and 60.4%)(χ^(2)=5.061,7.596,both P<0.05).The scores of quality of life in both groups increased significantly(t=35.585,35.830,P<0.05),with a significantly greater increase in the combination group than in the control group(t=3.373,11.264,P<0.05).The levels of carcinoembryonic antigen(CEA)and cytokeratin 19 fragment antigen 21-1(Cyfra21-1)in both groups significantly decreased(t=16.691-28.013,P<0.05),with a significantly greater reduction in the combination group than in the control group(t=2.175-8.658,both P<0.05).There were no significant differences between the two groups in the incidence of gastrointestinal reactions,anemia,leukocyte count decrease,fatigue,and arrhythmia(P>0.05).The incidence of rash in the control group(56.2%)was significantly higher than that in the combination group(29.2%)(χ^(2)=7.195,P<0.05).Conclusion\The combination of AiRuiKa and Endostar in the treatment of advanced NSCLC can im

关 键 词：癌 非小细胞肺 血管内皮生长因子类 程序性细胞死亡受体1 实体肿瘤疗效评价标准 生物标记 肿瘤 治疗结果 

分 类 号：R730.26[医药卫生—肿瘤] R977.6[医药卫生—临床医学]